Fosaprepitant
From Wikipedia, the free encyclopedia
 |
|
|
Fosaprepitant
|
|
| Systematic (IUPAC) name | |
| [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid | |
| Identifiers | |
| CAS number | 265121-04-8 (dimeglumine) |
| ATC code | A04 |
| PubChem | |
| Chemical data | |
| Formula | C23H22F7N4O6P |
| Mol. mass | 614.406 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | >95% (aprepitant) |
| Metabolism | To aprepitant |
| Half life | 9 to 13 hours (aprepitant) |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
, |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Intravenous |
Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant.
It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 .[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2]
[edit] References
- ^ Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy. Retrieved on 2008-03-15.
- ^ European Public Assessment Report for Ivemend (from the EMEA website). Retrieved on 2008-03-15.
|
|||||||||||||||||||||||||||||
|
||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
